---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-217100"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-05-11T21:10:04+00:00"
generated_at: "2026-05-11T21:14:19.874205+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere closes $525M 0.50% convertible note offering; uses proceeds to repurchase $221.4M of 2029 notes

## Summary
- Closed offering of $525M aggregate principal of 0.50% Convertible Senior Notes due 2032; net proceeds est. $508.5M.
- Initial conversion price ~$64.90/share (15.4078 shares per $1,000 principal); notes mature May 15, 2032.
- To repurchase $221.4M of outstanding 2.25% 2029 notes for approx. $350.9M, including accrued interest.
- Remaining net proceeds for general corporate purposes, including commercialization and R&D.
- Underwriters' over-allotment option fully exercised; offering upsized from $400M to $475M then to $525M.

## SEC filing metadata
- accession: 0001193125-26-217100
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-05-11T21:10:04+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/0001193125-26-217100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/d38424d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-217100
- JSON: https://secwatch.observer/filing/0001193125-26-217100.json
- Plain text: https://secwatch.observer/filing/0001193125-26-217100.txt

## Key facts
- Debt Financings
  Travere Therapeutics, Inc. incurred convertible notes of $525.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.50% maturing May 15, 2032.
  - Instrument: convertible notes
  - Principal: $525.0 million aggregate principal amount
  - Counterparty: U.S. Bank Trust Company, National Association
  - Rate: 0.50%
  - Maturity: May 15, 2032
  - Event: incurrence
  source text: completed its registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/0001193125-26-217100-index.htm
- Material Agreements
  Travere Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters valued at $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032 (effective 2026-05-11).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters
  - Value: $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032
  - Effective: 2026-05-11
  source text: On May 11, 2026 (the “Closing Date”), Travere Therapeutics, Inc. (the “Company”) completed its registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032 (such notes, the “Notes,” and such offering, the “Offering”) pursuant to the underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/0001193125-26-217100-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.